Login to Your Account

Onyx, Bayer Start 9006 Phase III Program In Renal Cell Carcinoma

By Kim Coghill

Tuesday, October 28, 2003
Onyx Pharmaceuticals Inc. and partner Bayer Corp. initiated a pivotal Phase III study in renal cell carcinoma with BAY 43-9006, a cancer candidate considered by some to be one of the most exciting products in development. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription